The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial (LEADER) led to a paradigm shift in the wider use of GLP-1RA from promising antihyperglycemic agents to cornerstone cardiometabolic therapies, demonstrating the significant reduction of major adverse cardiovascular events (MACE) with the use of liraglutide in the population with type 2 diabetes mellitus (T2DM) [12, 13]
Cell 171 , 372384.e12 (2017)
Diet-related factors, physical activity, and weight status in Polish adults
[DOI] [PubMed] [Google Scholar] 26.Su L, Xu G, Shen J, Tuo Y, Zhang X, Jia S, et al
If you need metabolic improvement, start with MOTS-c
Aetna Medicare Advantage plans Some Medicare Advantage plans have started covering GLP-1 medications for weight loss, though this is still uncommon